Current issues in the clinical management of invasive candida infections - the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Karthaus, M ^a   Ruping M J G T ^b   Cornely, O A ^b,c   Steinbach, A ^b   Groll, A H ^d   Lass Florl C ^e   Ostermann, H ^f   Ruhnke, M ^g   Vehreschild, J J ^b  

^a Klinikum Neuperlach   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antifungal agents; Candida spp; Systemic infection; Yeast

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDEMIA; CENTRAL VENOUS CATHETER; DRUG EFFICACY; HUMAN; INTRAVENOUS CATHETER; INVASIVE CANDIDIASIS; MATHEMATICAL MODEL; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DATA COLLECTION; GERMANY; HUMANS; INTERNET; MICROBIAL SENSITIVITY TESTS; QUESTIONNAIRES;

CANDIDA;

EID: 80052790647     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01988.x     Document Type: Article

References (35)

1. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
2. Rex JH, Walsh TJ, Sobel JD et al. Practice Guidelines for the Treatment of Candidiasis. Clin Infect Dis 2000; 30: 662-78 No abstract available. [Record as supplied by publisher].
3. Pappas PG, Rex J, Sobel JD et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
4. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
5. Bohme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
6. Vehreschild JJ, Rüping MJGT, Cornely OA. ClinicalSurveys.net - A Web-based Research Portal for Rare Diseases. Tokyo: ISHAM2009, 2009.
7. Menzin J, Meyers JL, Friedman M et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009; 66: 1711-7.
8. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
9. Parkins MD, Sabuda DM, Elsayed S et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60: 613-8.
10. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
11. DiNubile MJ, Hille D, Sable CA et al. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 2005; 50: 443-9.
12. Betts R, Glasmacher A, Maertens J et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106: 466-73.
13. Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
14. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30.
15. Lewis RE. Overview of the changing epidemiology of candidemia. Curr Med Res Opin 2009; 25: 1732-40.
16. Labelle AJ, Micek ST, Roubinian N et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-72.
17. Klevay MJ, Horn DL, Neofytos D et al. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2009; 64: 152-7.
18. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
19. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
20. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
21. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
22. Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8.
23. Bougnoux ME, Kac G, Aegerter P et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 2008; 34: 292-9.
24. Dimopoulos G, Ntziora F, Rachiotis G et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106: 523-9, table of contents.
25. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33: 1959-67.
26. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21: 994-6.
27. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34: 591-9.
28. Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007; 13: 788-93.
29. Nucci M, Colombo AL, Silveira F et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998; 19: 846-50.
30. Horn DL, Ostrosky-Zeichner L, Morris MI et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 2010; 29: 223-9.
31. Karthaus M, Hebart H, Einsele H et al. Long-term survival in patients with acute leukemia and chronic disseminated candidiasis despite minimal antileukemic therapy. Haematologica 2006; 91: 1422-3.
32. Glockner A, Steinbach A, Vehreschild JJ et al. Treatment of invasive candidiasis with echinocandins. Mycoses 2009; 52: 476-86.
33. Edwards JE Jr, Bodey GP, Bowden RA et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997; 25: 43-59.
34. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.
35. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Med 2009; 35: 206-14.